Dr. Aaron Scott, MD
Claim this profileUniversity of Arizona Cancer Center
Studies Colorectal Cancer
Studies Pancreatic Cancer
12 reported clinical trials
25 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
RAS negative
MSH2 positive
2Pancreatic Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Aaron Scott, MD is currently running
Fruquintinib
for Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
Recruiting3 awards Phase 46 criteria
Atezolizumab + Cabozantinib
for Pancreatic Cancer
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed through overall response rate (ORR), disease control rate (DCR), median overall survival (mOS), and median progression free survival (mPFS). Safety and tolerability of combination cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed and immune profiling pre- and post-treatment will be explored.
Recruiting1 award Phase 212 criteria
More about Aaron Scott, MD
Clinical Trial Related8 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Aaron Scott, MD has experience with
- SM08502
- Pembrolizumab
- Nab-paclitaxel
- Gemcitabine
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
- Nogapendekin Alfa
Breakdown of trials Aaron Scott, MD has run
Colorectal Cancer
Pancreatic Cancer
Pancreatic Adenocarcinoma
Lynch Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aaron Scott, MD specialize in?
Aaron Scott, MD focuses on Colorectal Cancer and Pancreatic Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are RAS negative.
Is Aaron Scott, MD currently recruiting for clinical trials?
Yes, Aaron Scott, MD is currently recruiting for 2 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Aaron Scott, MD has studied deeply?
Yes, Aaron Scott, MD has studied treatments such as SM08502, Pembrolizumab, Nab-paclitaxel.
What is the best way to schedule an appointment with Aaron Scott, MD?
Apply for one of the trials that Aaron Scott, MD is conducting.
What is the office address of Aaron Scott, MD?
The office of Aaron Scott, MD is located at: University of Arizona Cancer Center, Tucson, Arizona 85724 United States. This is the address for their practice at the University of Arizona Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.